Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 6/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.55 |
| ▸ | TTK | P33981 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.50 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.50 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | FADS1 | O60427 | 1/20 | 0.49 |
| ▸ | ITK | Q08881 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12907168 | 0.86 | PRKAG1 (0.68) | JAK2PRKAG1PRKAA1PRKAB1DYRK1A | |
| SCHEMBL627808 | 0.85 | PDPK1 (0.55) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL31032738 | 0.85 | PDPK1 (0.55) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL214502 | 0.83 | CNR2 (0.58) | TTKPRKAG1PRKAA1PRKAB1 | |
| SCHEMBL28707850 | 0.82 | ALDH1A1 (0.48) | KDM4EALDH1A1MAPTJAK2PDPK1 | |
| SCHEMBL1043754 | 0.81 | DYRK1A (0.56) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2661165 | 0.81 | BTK (0.51) | JAK2PDPK1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL11752456 | 0.81 | TTK (0.64) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL28577811 | 0.80 | PRKAG1 (0.60) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL5952020 | 0.80 | ALDH1A1 (0.53) | KDM4EALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110818683-B | 2-pyridine substituted urea structure small molecule compound and synthesis and application thereof | 中国科学院上海药物研究所 | 2023-04-14 | — | — | CN | disclosed |
| EP-2552211-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-02-06 | — | — | EP | disclosed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| WO-2011120025-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011120025-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
| EP-1966152-A2 | GLUCOKINASE ACTIVATORS | Takeda Pharmaceutical Company Limited (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | LEXICON PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | LEXICON PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-10-18 | — | — | US | disclosed |
| WO-2007075847-A2 | GLUCOKINASE ACTIVATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075847-A2 | GLUCOKINASE ACTIVATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | WO | disclosed |
| EP-0090972-B1 | INDAZOLE DERIVATIVES | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1990-05-30 | — | — | EP | disclosed |
| US-4751302-A | ANTIINFLAMMATORY, ANTIULCER AGENTS, ANALGESICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1988-06-14 | — | — | US | disclosed |
| US-4533731-A | ANTIINFLAMMATORY AGENTS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1985-08-06 | — | — | US | disclosed |
| EP-0090972-A2 | Indazole derivatives | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1983-10-12 | — | — | EP | disclosed |
| US-4084053-A | YELLOW AND ORANGE DYES, PYRIMIDINO(4',5':5,6)-1,2,4-TRIAZINO(4,3-BETA)INDAZOLES | CIBA-GEIGY CORPORATION (US) | 1978-04-11 | — | — | US | disclosed |
| US-4017479-A | Cationic indazole-azo-5-amino pyrazole dyestuffs | CIBA-GEIGY AG (CH) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | KDM4E 2963/4885ALDH1A1 1527/4885MAPT 3294/4885 |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K20 | KDM4E 1346/4885ALDH1A1 1337/4885MAPT 3359/4885 |
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | TNF, IL6, CXCL8 | KDM4E 4283/4885ALDH1A1 752/4885MAPT 1069/4885 |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | CPT1B, CPT1A, SHBG | KDM4E 3229/4885ALDH1A1 1249/4885MAPT 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.